Alizadehasl, Azin http://orcid.org/0000-0002-8550-1378
Mohseni, Mina http://orcid.org/0000-0002-3047-1554
Roudini, Kamran http://orcid.org/0000-0003-0166-0505
Firoozbakhsh, Parisa http://orcid.org/0000-0002-7383-8782
Article History
Received: 8 March 2023
Accepted: 11 March 2024
First Online: 15 March 2024
Declarations
:
: Fully informed consent was obtained from the patients for being involved in this study. They were fully educated about the potential risks and benefits of continuing and discontinuing trastuzumab, and were informed about the protective effects of beta-blockers, ACEIs, and spironolactone against TIC at the cardio-oncology clinic of Rajaie Cardiovascular Medical and Research Center. The patients were monitored by a board-certified cardio-oncologist during the treatment period and if any cardiac event occurred during this time, the patient received the proper treatment. This study protocol was reviewed and approved by the Ethics Committee of Rajaie Cardiovascular Medical and Research Center.
: All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
: The authors declare no competing interests.